Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 218-225

  Milberg, Peter ^a   Eckardt, Lars ^a   Bruns, Hans Jürgen ^a   Biertz, Julia ^a   Ramtin, Shahram ^a   Reinsch, Nico ^a   Fleischer, Dirk ^a   Kirchhof, Paulus ^a   Fabritz, Larissa ^a   Breithardt, Günter ^a   Haverkamp, Wilhelm ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE;

ACTION POTENTIAL; AFTERHYPERPOLARIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART REPOLARIZATION; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; RABBIT; TORSADE DES POINTES;

ANIMALS; ANTI-BACTERIAL AGENTS; ARRHYTHMIA; AZITHROMYCIN; BLOOD PRESSURE; CLARITHROMYCIN; ELECTROCARDIOGRAPHY; ERYTHROMYCIN; HEART; HEART RATE; LONG QT SYNDROME; MALE; RABBITS; TIME FACTORS; TORSADES DE POINTES;

EID: 0036784524     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.037911     Document Type: Article

References (28)

1. Antzelevitch C and Sicouri S (1994) Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 23:259-277.
2. Antzelevitch C, Sun ZQ, Zhang ZQ, and Yan GX (1996) Cellular and ionic mechanisms underling erythromycin-induced long QT intervals and Torsade de Pointes. J Am Coll Cardiol 28:1836-1848.
3. Daleau P, Lessard E, Groleau MF, and Turgeon J (1995) Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. Angiology 48:3010-3016.
4. Dessertenne F (1966) La tachycardie ventriculaire à deux foyers opposés variables. Arch Mal Coeur 59:263-272.
5. Eckardt L, Breithardt G, and Haverkamp W (2002) Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT-prolongation. J Pharmacol Exp Ther 300:64-71.
6. Eckardt L, Haverkamp W, Borggrefe M, and Breithardt G (1998a) Experimental models of torsade de pointes. Cardiovasc Res 39:178-193.
7. Eckardt L, Haverkamp W, Mertens H, Johna R, Clague JR, Boggrefe M, and Breithardt G (1998b) Drug-related torsade de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol and erythromycin. J Cardiovasc Pharmacol 32:425-434.
8. Fazekas T, Krassoi I, Lengyel C, Varro A, and Papp JG (1998) Suppression of erythromycin-induced early afterdepolarizations and torsade de pointes ventricular tachycardia by mexiletine. Pacing Clin Electrophysiol 21:147-150.
9. Franz MR, Kirchhof PF, Fabritz CL, and Zabel M (1995) Computer analysis of monophasic action potentials: manual validation and clinically pertinent applications. Pacing Clin Electrophysiol 18:1666-1678.
10. Freedman RA, Anderson KP, Green LS, and Mason JW (1987) Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 59:168-169.
11. Habbab MA and el Sherif N (1990) Drug-induced torsades de pointes: role of early afterdepolarizations and dispersion of repolarization. Am J Med 89:241-246.
12. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, et al. (2000) The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications: report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47:219-233.
13. Hondeghem LM, Carlsson L, and Duker G (2001) Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103:2004-2013.
14. January CT, Gong Q, and Zhou Z (2000) Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2. J Cardiovasc Electrophysiol 11:1413-1418.
15. Katapadi K, Kostandy G, Katapadi M, Hussain KM, and Schifter D (1997) A review of erythromycin-induced malignant tachyarrhythmia-torsade de pointes. A case report. Angiology 48:821-826.
16. Kurita T, Ohe T, Maeda K, Shimizu W, Takaki H, Aihara N, Kamakura S, and Shimomura K (1994) Bradycardia-related long QT syndrome and torsade de pointes: comparison between patients with complete AV block and with sinus bradycardia. Jpn Heart J 35:145-146.
17. Lee KL, Jim MH, Tang SC, and Tai YT (1998) QT prolongation and Torsades de Pointes associated with clarithromycin. Am J Med 104:395-396.
18. Nattel S, Ranger S, Talajic M, Lemery R, and Roy D (1990) Erythromycin-induced long QT syndrome: concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 89:235-238.
19. Ohtani H, Taninaka C, Hanada E, Kotaki H, Sato H, Sawada Y, and Iga T (2000) Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin and azithromycin in rats. Antimicrob Agents Chemother 44:2630-2637.
20. Rubart M, Pressler ML, Pride HP, and Zipes DP (1993) Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 88:1832-1844.
21. Samarendra P, Kumari S, Evans SJ, Sacchi TJ, and Avarro V (2001) QT prolongation associated with azithromycin/amiodarone combination. Pacing Clin Electrophysiol 24:1572-1574.
22. Shaffer DN and Singer SJ (2001) Macrolide Antibiotics and Torsade de Pointes Postmarketing Analysis, Office of Postmarketing Drug Risk Assessment, Food and Drug Administration, Washington, DC.
23. Shimizu W, Tanaka K, Suenaga K, and Wakamoto A (1991) Bradycardia-dependent early afterdepolarizations in a patient with QTU prolongation and torsade de pointes in association with marked bradyeardia and hypokalemia. Pacing Clin Electrophysiol 14:1105-1111.
24. Verduyn SC, Vos MA, van-der ZJ, Van-der HF, Wellens HJ (1997) Role of interventricular dispersion of repolarization in acquired Torsade-de-Pointes arrhythmias: reversal by magnesium. Cardiovasc Res 34:453-463.
25. Volders PG, Vos MA, Szabo B, Sipido KR, de-Groot SH, Gorgels AP, Wellens HJ, and Lazzara R (2000) Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 46:376-392.
26. Wasmer K, Hindricks G, and Kottkamp H (1999) Clarithromycin assoziierte Synkope als Erstmanifestation eines angeborenen langes QT-Syndroms? Intensivmed 36:534-540.
27. Kr: implications for torsade de pointes and reverse use-dependence. Circulation 93:407-411.
28. Zabel M, Hohnloser SH, Behrens S, Li Y-G, Woosley RL, and Franz MR (1997) Electrophysiologic features of torsade de pointes: insights from a new rabbit heart model. J Cardiovasc Electrophysiol 8:1148-1158.